We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA’s PRAC Recommends Additional Zinbryta Restrictions
EMA’s PRAC Recommends Additional Zinbryta Restrictions
The European Medicines Agency’s pharmacovigilance committee recommended additional restrictions on Biogen’s Zinbryta (daclizumab), after reviewing its effects on the liver.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor